Your browser is no longer supported. Please, upgrade your browser.
Settings
HUGE [NASD]
FSD Pharma Inc.
Index- P/E- EPS (ttm)- Insider Own12.91% Shs Outstand35.99M Perf Week4.29%
Market Cap61.19M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float33.97M Perf Month-1.16%
Income- PEG- EPS next Q- Inst Own2.53% Short Float2.78% Perf Quarter-3.95%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio2.35 Perf Half Y-17.87%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-48.95%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.28 - 4.44 Perf YTD8.97%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-62.16% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low31.25% ATR0.08
Employees9 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)50.40 Volatility4.50% 5.09%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.31 Prev Close1.70
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume401.97K Price1.68
Recom- SMA203.35% SMA50-3.89% SMA200-8.89% Volume59,875 Change-1.18%
Jul-28-21 10:05AM  
Jul-27-21 08:47AM  
Jun-03-21 09:00AM  
May-26-21 06:59PM  
May-17-21 03:18AM  
May-12-21 12:49PM  
May-10-21 08:30AM  
May-05-21 04:23PM  
08:30AM  
May-03-21 07:30AM  
Apr-26-21 09:04PM  
Apr-23-21 09:00AM  
Apr-05-21 07:30AM  
07:30AM  
Mar-31-21 05:00PM  
Mar-16-21 09:56PM  
Mar-08-21 07:00AM  
07:00AM  
Feb-11-21 08:40AM  
Jan-26-21 07:30PM  
Jan-22-21 04:30PM  
Dec-15-20 08:35AM  
Nov-12-20 05:00PM  
Oct-29-20 07:30AM  
Oct-21-20 07:30AM  
Oct-16-20 07:30AM  
Oct-05-20 07:30AM  
Sep-28-20 02:30AM  
Aug-31-20 02:30AM  
Aug-20-20 05:45AM  
Aug-07-20 05:45PM  
05:45PM  
Aug-06-20 05:00PM  
05:00PM  
Jul-31-20 04:49PM  
09:00AM  
Jul-30-20 02:30AM  
Jul-13-20 02:30AM  
02:30AM  
Jun-23-20 09:00AM  
Jun-22-20 02:30AM  
Jun-09-20 11:39AM  
05:47AM  
Jun-04-20 09:43AM  
Jun-03-20 04:20PM  
02:30AM  
02:30AM  
May-21-20 08:30AM  
08:30AM  
May-14-20 05:12PM  
Mar-23-20 09:17AM  
Mar-10-20 09:00AM  
Mar-09-20 08:30AM  
08:30AM  
Mar-06-20 01:14PM  
Mar-04-20 02:30AM  
02:30AM  
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.